poisar

Stocks · News reference

US Stocks Mixed; Cardinal Health Shares Jump After Q4 Results

BenzingaAvi Kapoor

US stocks mixed, Dow up 150 points. Industrials gain 1%, communication services fall 1.1%. Cardinal Health (NYSE: CAH) up 8%. Oil up 0.4%, gold up 0.6%.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. The Motley FoolBrendan Coffey

    AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

    AbbVie has successfully diversified beyond its blockbuster Humira with strong immunology drugs (Skyrizi and Rinvoq), while Pfizer is leveraging its cash position to build oncology and GLP-1 pipelines. Despite AbbVie's stronger growth trajectory, Pfizer offers better valuation metrics with lower P/E and P/S ratios, making it the preferred choice for long-term value investors willing to wait for new product launches.

  2. Zacks Investment ResearchNa

    Is Generics Still a Quiet Profit Engine for Cardinal Health?

    Cardinal Health's generics business continues to be a steady profit contributor, with fiscal 2026 volume growth exceeding long-term planning assumptions of 2-3%. The company expects fiscal 2027 to benefit from new generic launches, brand-to-generic conversions, and stable Red Oak program dynamics, supporting projected Pharma segment profit growth of 8-11%. Peers McKesson and Cencora also show strength in their pharmaceutical distribution and generics portfolios.

  3. The Motley FoolJonathan Ponciano

    Cardinal Health's CFO Moved $9.9 Million of Stock. Here's What Long-Term Investors Should Know

    Cardinal Health's CFO Aaron Alt sold 42,000 shares worth $9.9 million on August 18, reducing his direct holdings to 20,495 shares. The sale occurred after the stock surged 57% over the past year. Despite the insider sale, the company maintains strong guidance with fiscal 2027 EPS projected at $12.40-$12.60 (13-15% growth), planned capital expenditures of $700 million, and at least $1 billion in share repurchases expected.